A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs B 244 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors AOBiome
- 10 Dec 2018 Planned End Date changed from 20 Nov 2018 to 20 Feb 2019.
- 10 Dec 2018 Planned primary completion date changed from 20 Nov 2018 to 20 Feb 2019.
- 09 Apr 2018 New trial record